168 related articles for article (PubMed ID: 29506494)
41. Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.
Zheng B; Qu Y; Wang J; Shi Y; Yan W
Cancer Genomics Proteomics; 2019; 16(3):221-228. PubMed ID: 31018952
[TBL] [Abstract][Full Text] [Related]
42. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
Andersson C; Fagman H; Hansson M; Enlund F
Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
[TBL] [Abstract][Full Text] [Related]
43. Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.
Lewin J; Garg S; Lau BY; Dickson BC; Traub F; Gokgoz N; Griffin AM; Ferguson PC; Andrulis IL; Sim HW; Kamel-Reid S; Stockley TL; Siu LL; Wunder JS; Razak ARA
Int J Cancer; 2018 Jan; 142(1):57-65. PubMed ID: 28891048
[TBL] [Abstract][Full Text] [Related]
44. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
[TBL] [Abstract][Full Text] [Related]
45. Targeted next-generation sequencing of matched localized and metastatic primary high-risk SCCs identifies driver and co-occurring mutations and novel therapeutic targets.
Lobl MB; Clarey D; Higgins S; Sutton A; Hansen L; Wysong A
J Dermatol Sci; 2020 Jul; 99(1):30-43. PubMed ID: 32595073
[TBL] [Abstract][Full Text] [Related]
46. Spatio-temporal mutation profiles of case-matched colorectal carcinomas and their metastases reveal unique de novo mutations in metachronous lung metastases by targeted next generation sequencing.
Kovaleva V; Geissler AL; Lutz L; Fritsch R; Makowiec F; Wiesemann S; Hopt UT; Passlick B; Werner M; Lassmann S
Mol Cancer; 2016 Oct; 15(1):63. PubMed ID: 27756406
[TBL] [Abstract][Full Text] [Related]
47. Genome-wide hypomethylation and specific tumor-related gene hypermethylation are associated with esophageal squamous cell carcinoma outcome.
Hoshimoto S; Takeuchi H; Ono S; Sim MS; Huynh JL; Huang SK; Marzese DM; Kitagawa Y; Hoon DS
J Thorac Oncol; 2015 Mar; 10(3):509-17. PubMed ID: 25514805
[TBL] [Abstract][Full Text] [Related]
48. Esophageal carcinosarcoma with basaloid squamous carcinoma and rhabdomyosarcoma components with TP53 mutation.
Amatya VJ; Takeshima Y; Kaneko M; Inai K
Pathol Int; 2004 Oct; 54(10):803-9. PubMed ID: 15482572
[TBL] [Abstract][Full Text] [Related]
49. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
50. Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.
Hatogai K; Fujii S; Kojima T; Daiko H; Doi T; Ohtsu A; Ochiai A; Takiguchi Y; Yoshino T
BMC Cancer; 2017 Jan; 17(1):36. PubMed ID: 28068934
[TBL] [Abstract][Full Text] [Related]
51. Next-Generation Sequencing for Patients with Sarcoma: A Single Center Experience.
Cote GM; He J; Choy E
Oncologist; 2018 Feb; 23(2):234-242. PubMed ID: 28860410
[TBL] [Abstract][Full Text] [Related]
52. Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing.
Jin Y; Shao Y; Shi X; Lou G; Zhang Y; Wu X; Tong X; Yu X
Oncotarget; 2016 Sep; 7(38):61755-61763. PubMed ID: 27528220
[TBL] [Abstract][Full Text] [Related]
53. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations.
Hollstein MC; Peri L; Mandard AM; Welsh JA; Montesano R; Metcalf RA; Bak M; Harris CC
Cancer Res; 1991 Aug; 51(15):4102-6. PubMed ID: 1855226
[TBL] [Abstract][Full Text] [Related]
54. Ampulla of Vater Carcinoma: Sequencing Analysis Identifies TP53 Status as a Novel Independent Prognostic Factor and Potentially Actionable ERBB, PI3K, and WNT Pathways Gene Mutations.
Mafficini A; Amato E; Cataldo I; Rusev BC; Bertoncello L; Corbo V; Simbolo M; Luchini C; Fassan M; Cantù C; Salvia R; Marchegiani G; Tortora G; Lawlor RT; Bassi C; Scarpa A
Ann Surg; 2018 Jan; 267(1):149-156. PubMed ID: 27611608
[TBL] [Abstract][Full Text] [Related]
55. Targeted Sequencing of Malignant Supratentorial Pediatric Brain Tumors Demonstrates a High Frequency of Clinically Relevant Mutations.
Cole BL; Pritchard CC; Anderson M; Leary SE
Pediatr Dev Pathol; 2018; 21(4):380-388. PubMed ID: 29173061
[TBL] [Abstract][Full Text] [Related]
56. Identification of molecular targets in vulvar cancers.
Palisoul ML; Mullen MM; Feldman R; Thaker PH
Gynecol Oncol; 2017 Aug; 146(2):305-313. PubMed ID: 28536037
[TBL] [Abstract][Full Text] [Related]
57. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
58. Next-generation sequencing-based clinical sequencing: toward precision medicine in solid tumors.
Wakai T; Prasoon P; Hirose Y; Shimada Y; Ichikawa H; Nagahashi M
Int J Clin Oncol; 2019 Feb; 24(2):115-122. PubMed ID: 30515675
[TBL] [Abstract][Full Text] [Related]
59. Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas.
Qin J; Chen B; Li C; Yan J; Lu H
Cancer Genet; 2021 Jan; 250-251():12-19. PubMed ID: 33217678
[TBL] [Abstract][Full Text] [Related]
60. Genome Sequencing in Esophageal Squamous Cell Carcinoma.
Pillai S; Maksemous N; Lam AK
Methods Mol Biol; 2020; 2129():217-240. PubMed ID: 32056181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
